Status:
COMPLETED
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
Hypertension
Hyperlipidemia
Eligibility:
All Genders
19-75 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate efficacy and safety of coadministered Irbesartan and Atorvastatin in patients with hypertension and hyperlipidemia.
Eligibility Criteria
Inclusion
- Aged between 19 and 75 years
- Signed informed consent
Exclusion
- At screening, SPB ≥ 180mmHg or DBP ≥ 110mmHg or LDL-C \> 250mg/dL or TG ≥ 400mg/dL
- Has a history of hypersensitivity to Angiotensin Ⅱ receptor blocker or HMG-CoA reductase inhibitor or component of this drug
- Has a history of multi-drug allergy
Key Trial Info
Start Date :
May 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2013
Estimated Enrollment :
230 Patients enrolled
Trial Details
Trial ID
NCT01442987
Start Date
May 1 2011
End Date
May 1 2013
Last Update
August 13 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
16 institutions including Seoul National University Hospital
Seoul, South Korea